HOPES RISE FOR MRNA CANCER VACCINE AFTER MODERNA TRIAL SHOWS PROMISE

Summary from the TLDR newsletter

Moderna's mRNA cancer vaccine, developed to target melanoma, might also treat a form of head and neck cancer. Data from an early trial showed a greater survival rate for patients who took Moderna's cancer vaccine alongside immunotherapy treatments. The news sent Moderna's share price soaring.